Kidney Failure, Presence of Donor Specific Antibodies
Conditions
Keywords
Donor specific antibodies, Kidney transplantation, Coated nanoparticles
Brief summary
Magnetic nanoparticles, coated with human leukocyte antigens (HLA) to capture anti-HLA antibodies with donor specificity (donor-specific antibodies, DSA), will be tested ex-vivo.
Detailed description
This project aims at developing a new method using human leukocyte antigens (HLA)-coated magnetic nanoparticles to remove donor-specific antibodies (DSA) from the patients' blood ex vivo, while trying to keep the blood unaffected after exposure to the particles. Nanoparticles will be engineered and tested ex vivo. While nanoparticles were successfully coated with macromolecules such as antibodies in the past, this is a new approach, which will be performed by the research group. The goal of this project is to capture DSA in patient blood ex vivo and to remove them by magnetic separation. Efficacy and safety of this procedure will be assessed, especially the interaction of these novel particles with other blood components such as coagulation factors or effector cells, which could produce inflammatory mediators. According analyses are initiated and carried out.
Interventions
None listed
Sponsors
University of Zurich
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* DSA in the blood as detected by Luminex® * Adults (\>18 years old) * Informed written consent
Exclusion criteria
* Inability to follow the procedures of the study, due to language problems, psychological disorders, social conditions or dementia * Pregnancy and/or breast feeding * Unwillingness to participate in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of DSA removed in a blood sample using HLA-coated magnetic nanoparticles | 1 day | Quantification of DSA removal using HLA-coated magnetic nanoparticles in comparison with blood treated with control nanoparticles (without HLA coating). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood coagulation (rotational thromboelastometry ROTEM, plasma clotting time) before and after treatment with HLA-coated magnetic nanoparticles | 1 day | Coagulation parameters as described will be evaluated in blood samples. The same analyses will be repeated after exposure to HLA-coated magnetic nanoparticles. |
| Inflammatory blood mediators (IL-6, MCP-1) before and after treatment with HLA-coated magnetic nanoparticles | 1 day | Inflammatory parameters as described will be evaluated in blood samples. The same analyses will be repeated after exposure to HLA-coated magnetic nanoparticles. |
Countries
Switzerland
Outcome results
None listed